COVID-19 clinical trials at UC Davis

6 research studies open to eligible people

Showing trials for

  • Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to eligible people ages 18 years and up

    This is a randomized, open label, adaptive platform trial to compare the effectiveness of antithrombotic and additional strategies for prevention of adverse outcomes in COVID-19 positive inpatients

    San Francisco 5391959, California 5332921 and other locations

  • Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients

    open to eligible people ages 2-17

    The purpose of this study was to confirm and to establish appropriate dosing and to evaluate the safety in pediatric participants ages 2 to <18 years with a history of Vaso-Occlusive Crisis (VOC) with or without Hydroxyurea/Hydroxycarbamide (HU/HC), receiving crizanlizumab for 2 years. The efficacy and safety of crizanlizumab was previously demonstrated in adults with sickle cell disease. The approach was to extrapolate from the pharmacokinetics (PK)/pharmacodynamics (PD) already established in the adult population. The study was designed as a Phase II, multicenter, open-label study.

    Fort Worth 4691930, Texas 4736286 and other locations

  • Immunosuppression Adjustment on COVID-19 Vaccination Response in Kidney Transplant Recipients

    open to eligible people ages 18 years and up

    Immunocompromised individuals, such as solid organ transplant (SOT) recipients are at high risk of COVID-19 associated complications and mortality. Retrospective studies so far have shown that a majority of SOT recipients did not develop appreciable anti-spike antibody response after a first, second, or even third dose of mRNA vaccine. Treatment with antimetabolites was associated with poor vaccine response. The goal of this study is 1) examine whether transient immunosuppression reduction improves the immune response to a third dose of SARS-CoV-2 mRNA vaccine in kidney transplant recipients and 2) to assess the safety of immunosuppression reduction before and after third dose SARS-CoV-2 mRNA vaccination.

    Sacramento 5389489, California 5332921

  • I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

    open to eligible people ages 18 years and up

    The goal of this project is to rapidly screen promising agents, in the setting of an adaptive platform trial, for treatment of critically ill COVID-19 patients. In this phase 2 platform design, agents will be identified with a signal suggesting a big impact on reducing mortality and the need for, as well as duration, of mechanical ventilation.

    Davis 5341704, California 5332921 and other locations

  • PET/CT Imaging in COVID-19 Patients

    open to eligible people ages 18 years and up

    This is a PET/CT study using the 18F-αvβ6-binding-peptide.The goal of this study is to evaluate this peptide in patients after infection with SARS CoV2.

    Sacramento 5389489, California 5332921

  • DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study

    “Volunteer for research and contribute to discoveries that may improve health care for you, your family, and your community!”

    open to all eligible people

    This study will seek to enroll immunocompromised patients with Lower Tract parainfluenza infection. It also contains a sub-study to enroll patients with severe COVID-19.

    Sacramento 5389489, California 5332921 and other locations

Our lead scientists for COVID-19 research studies include .

Last updated: